BioWorld

Dec. 3, 2002

Osteoporosis News Continues: Unigene Entering $10M Deal

Aastrom Enters Fusion Deal, Selling Up To $12M In Stock

MGI Raises $21M For Palonosetron Milestone Payments To Helsinn

MGI Pharma Inc. on Monday lined its pockets with $21 million in a private placement, funding sufficient to cover two remaining milestone payments as part of a license agreement with Helsinn Healthcare SA. (BioWorld Today) Read More

Genesis Bioventures To Merge With Innathera, Raise $15M

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...

BioWorld

Dec. 3, 2002

Osteoporosis News Continues: Unigene Entering $10M Deal

Aastrom Enters Fusion Deal, Selling Up To $12M In Stock

Other News To Note

Appointments And Advancements

MGI Raises $21M For Palonosetron Milestone Payments To Helsinn

Genesis Bioventures To Merge With Innathera, Raise $15M

Today's news in brief

Today's news in brief

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

CTAD 2025: The challenges of combination therapies for dementia

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle